Lv4
610 积分 2024-01-29 加入
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
1天前
待确认
Topoisomerase I inhibitors: Challenges, progress and the road ahead
1天前
待确认
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
2天前
已完结
Tissue factor: a neglected role in cancer biology
16天前
已完结
An overview of anticancer platinum N-heterocyclic carbene complexes
1个月前
已完结
Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab
2个月前
已完结
Potential benefit of oral calcium/vitamin D administration for prevention of symptomatic hypocalcemia after total thyroidectomy
3个月前
已关闭
A review of the novel tissue factor antibody–drug conjugate: Tisotumab vedotin
4个月前
已完结
Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in second-line or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A global, randomized, open-label, phase III study
4个月前
已关闭
皖公网安备34019202002308
